Analysis
General Medicine has raised $120 million in Series B funding led by Andreessen Horowitz, with Matrix, VXI Capital, Eli Lilly and Company, Mercy Health (through Granger Management) and BoxGroup also participating, the company said this week.
The company operates what it calls a "healthcare store" — a nationwide platform where patients can search, compare and buy care across more than 2,900 products and services, from medications and lab tests to telehealth visits and select procedures, with transparent pricing shown upfront for both insured and uninsured customers, according to a company announcement.
"Everyone's building a healthcare AI agent that can tell you what you might need. What's missing is the infrastructure" to actually access it, CEO TJ Parker said. Parker previously co-founded PillPack, the online pharmacy Amazon acquired for roughly $1 billion in 2018, and his co-founders include Chief Product Officer Ashwin Muralidharan and President Elliot Cohen.
“"Everyone's building a healthcare AI agent that can tell you what you might need.”
Price Transparency, Again
General Medicine's pitch echoes PillPack's own playbook of making a notoriously opaque part of healthcare simple to shop, but the target this time is far broader: not just prescriptions, but labs, specialist visits and procedures, where pricing is often buried in payer contracts rather than posted anywhere a patient can see before booking. That's a harder problem than drug pricing, which at least starts from a published list price.
The company says it has grown from a May 2025 nationwide launch to a catalog of more than 2,900 services, with an average customer satisfaction score of 80 and 83% of customers reporting they addressed a previously delayed health need through the platform. Those are strong engagement signals, though they are self-reported company metrics rather than independently audited figures, and say nothing yet about repeat usage or unit economics at scale.
Eli Lilly and Mercy Health's parent Granger Management joining the round signals both a drugmaker and a hospital system want a stake in whichever company ends up owning the patient-facing storefront for healthcare pricing, a layer currently split across hundreds of insurer portals and provider websites.
